Form 10-Q · Quarterly report
Albemarle Corporation 10-Q, filed Aug 5, 2026
- Filed
- CIK
- 0000915913
- Accession no.
- 0000915913-26-000102
Summary
Albemarle reported second-quarter 2026 net sales of $1.7 billion, up 31% year over year, with adjusted EBITDA up 155% on strong results in its Energy Storage and Specialties segments. The company completed the first-quarter 2026 sale of its controlling ownership in Refining Solutions and its 50% interest in the Eurecat S.A. joint venture for about $648 million in pre-tax proceeds, and it expects flat to slightly lower Energy Storage sales volumes for the year after a fire at the Talison joint venture's CGP3 plant at Greenbushes, with remediation targeted for completion in the second half of 2026.
Key points
- Second-quarter 2026 gross profit was $590.3 million at a 33.9% margin, up from $196.9 million and 14.8% a year earlier.
- Cash flow from operations in the first six months of 2026 was $1.1 billion, up 96% year over year.
- Following the Refining Solutions divestiture on March 2, 2026, Albemarle reports results in two segments: Energy Storage and Specialties.
- Albemarle said it does not expect a material direct impact from U.S. or international tariffs proposed or imposed to date.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview We are a world leader in transforming essential resources into critical ingredients for mobility, energy, connectivity, and health. Our purpose is to enable a more resilient world. We partner to pioneer new ways to move, power, connect, and protect. The end markets we serve include grid storage, automotive, aerospace, conventional energy, electronics, construction, agriculture and food, pharmaceuticals and medical devices. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.